Evosep, a worldwide chief in proteomics options, is proud to announce its relocation to new headquarters in Odense. This transfer will considerably improve the corporate’s potential to advance the usage of proteomics as an important instrument for the pharmaceutical and biotech industries. Constructing on current strategic initiatives, the brand new facility will function a hub for continued innovation, reinforcing Evosep’s dedication to bettering drug discovery, growth, and diagnostics by way of high-precision proteomics.
The choice to relocate is a part of Evosep’s technique to develop capabilities and speed up its mission to revolutionize proteomics. With the launch of Evosep Biolabs, a middle of excellence for high-throughput proteomics specializing within the evaluation of plasma proteomics samples, the brand new headquarters will assist the quickly rising demand for superior proteomics methods. These methods are important for measuring the advanced profiles of recent drug modalities, together with biologics, cell and gene therapies, that are more and more shaping the way forward for the pharmaceutical and biotech industries.
To additional assist the seamless integration of its applied sciences into pharmaceutical and controlled laboratories, Evosep is releasing Set up Qualification (IQ) and Operational Qualification (OQ) protocols. These IQ/OQ service choices are designed to make sure that Evosep’s proteomics options meet the stringent high quality and compliance requirements required in regulated pharma environments. By offering complete IQ/OQ companies together with progressive (patent-pending) OQ methodology and totally automated reporting, Evosep permits pharma and Contract Analysis Group (CRO) labs to rapidly and reliably qualify and combine its techniques, guaranteeing optimum efficiency and regulatory alignment. This initiative underscores Evosep’s ongoing dedication to empowering pharmaceutical firms with environment friendly, compliant instruments to drive innovation in drug discovery and growth.
“Our new headquarters in Odense will enable us to scale up our operations and push the boundaries of what is doable in proteomics,” mentioned Morten Bern, CEO of Evosep. “With the elevated demand from pharma and biotech for extra exact and scalable drug profiling strategies, this transfer permits us to raised assist the trade with cutting-edge proteomics workflows, guaranteeing quicker, extra dependable outcomes.”
As a part of Evosep’s ongoing efforts to increase its attain inside the pharmaceutical sector, the corporate has additionally strengthened its strategic partnership with SCIEX, a worldwide chief in analytical instrumentation. Evosep and SCIEX have prolonged their co-marketing settlement, additional aligning their efforts to ship end-to-end options that handle the evolving wants of pharmaceutical and biotech firms.
The synergy between Evosep and SCIEX’s applied sciences and experience will present unmatched options for drug growth pipelines, enabling pharma firms to research a wider vary of drug modalities extra effectively and at a bigger scale. By fostering a powerful collaborative ecosystem with key trade gamers, Evosep goals to solidify its place as a pivotal companion to pharmaceutical R&D.
This strengthened partnership with SCIEX permits us to ship extra sturdy, scalable options for the pharma and biotech industries, instantly addressing their want for high-throughput, high-sensitivity proteomics. As we proceed to develop, these partnerships are important for our mission to make proteomics a robust instrument for the event of life-saving medicine.”
Eric Grumbach, VP of Enterprise Improvement – Pharma
With its new headquarters, enhanced expertise pool, and expanded strategic partnerships, Evosep is well-positioned to speed up its mission of remodeling proteomics right into a broadly accessible and dependable instrument for drug discovery and growth.
